Boehringer Ingelheim to Develop NASH Candidate Based On Dicerna's GalXC Platform

Germany-based Boehringer Ingelheim has accepted Dicerna Pharmaceuticals Inc's DRNA GalXC RNAi candidate for advancement under the existing agreement between the companies to discover and develop novel therapies for the treatment of chronic liver diseases.
Dubbed DCR-LIV2, the compound will be investigated for the treatment of nonalcoholic steatohepatitis (NASH).
Acceptance of DCR-LIV2 as a development candidate triggered an undisclosed preclinical milestone payment to Dicerna, which the Company expects to receive in the second quarter of 2021.
Under the terms of the existing agreement, Dicerna is eligible to receive up to $170 million in potential additional milestone payments related to DCR-LIV2.
Dicerna is also eligible to receive tiered mid-single-digit royalties on potential global net sales.
Price Action: DRNA shares are up 1.96% at $29.70 during the market session on the last check Monday.